NASDAQ
MIST
Last Price
US $1.32
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Milestone Pharmaceuticals Inc. cash flow to debt ratio of -84.01% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Milestone Pharmaceuticals Inc.'s free cash flow has decreased 70.85% from $-28.88M last year to $-49.34M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Milestone Pharmaceuticals Inc.'s debt to equity ratio is 3.81, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial stability - Healthy debt to equity ratio development.
Milestone Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 4.17 last year to 3.81 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
Milestone Pharmaceuticals Inc. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Milestone Pharmaceuticals Inc.'s interest coverage ratio is -9.30, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
Milestone Pharmaceuticals Inc. has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Milestone Pharmaceuticals Inc.'s short-term assets of $111.92M exceed its short-term liabilities of $13.98M
Decreasing performance - ROA.
Milestone Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Milestone Pharmaceuticals Inc.'s return on equity of -339.38%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Milestone Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Milestone Pharmaceuticals Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Milestone Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Milestone Pharmaceuticals Inc. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Milestone Pharmaceuticals Inc.'s yearly earnings has decreased 51.88% since last year from $-41.52M to $-63.06M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Milestone Pharmaceuticals Inc.'s yearly revenue has increased % since last year from $0.00 to $1.55M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -37.64% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Milestone Pharmaceuticals Inc.'s 3-year revenue CAGR of -32.38% is negative, indicating declining revenue over the past 3 years
Decreasing performance - Revenue consistency.
Milestone Pharmaceuticals Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Milestone Pharmaceuticals Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Milestone Pharmaceuticals Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Milestone Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Milestone Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Milestone Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Milestone Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Milestone Pharmaceuticals Inc. has a price-to-book ratio of 4.48x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Milestone Pharmaceuticals Inc. has a price-to-sales ratio of 59.70x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-339.38%
Return on equity
ROIC: -37.64%
Valuation History
-1.8X
Price to Earnings
EV/EBITDA: -2.8X
Cash flow
Profit margin
-3.17%
(FY vs FY)
Cash flow Y/Y
0.56%
(FY vs FY)
Fair Value
Market $1.32
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.